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ABSTRACT
Despite the fact that E. coli supports limited posttranslational modification, this
bacterium has been universally used as the expression system of choice. Expression of
modified proteins in E. coli may lead to expression of recombinant proteins that lack
essential immunomodulatory or catalytic components essentials for infectious processes.
Previously in our laboratory, pMptb#28 plasmid containing a 4.8 kb insert from M.
paratuberculosis has been identified which expressed 16 kDa recombinant protein in E.
coli and 19 kDa recombinant protein in Mycobacterium smegmatis. The objective of this
study is to identify the ORF sequence, investigate possible posttranslational modification
and characterize the protein forms in the two hosts. Earlier in the study, the genome
sequence for M. paratuberculosis was not available and therefore sequencing both the 5’
and 3’ ends of the 4.8 kb insert did not help in the identification of the ORF. However,
unidirectional Exonuclease deletion resulted in identification of subclones containing
possible ORF sequence. Later on, the publication of the M. paratuberculosis genome
sequence along with BLAST analysis of sequences from the subclones resulted in the
identification of 486 bp ORF with significant identity to that from M. tuberculosis and M.
leprae. Cloning of the 486 ORF coding sequence in E. coli resulted in the expression of
16 kDa protein similar to the calculated predicted size of translated peptide. Cloning of
the 486 bp ORF coding sequence in M. smegmatis resulted in the expression of 19 kDa
protein similar to that from M. paratuberculosis. The 16/19 kDa forms of the same
protein were verified using rabbit anti-M. paratuberculosis antibodies adsorbed in E. coli
and M. smegmatis lysates. The size of the 19 kDa proteins was not reduced following
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treatment with deglycosylation enzymes in absence of any enzyme inhibitors. The 19
kDa product was confirmed not be a glycoprotein when failed to react with ConA stain.
The 16/19 kDa forms of the protein were evaluated against T-lymphocytes from Crohn’s
disease patients and normal controls. T- proliferation assay included controls such as
PHA and PPD from M. paratuberculosis. There was not a significant difference between
the two forms of the protein (16/19 kDa) against T-cell response from both populations.
Overall, the study identified the ORF of the 19 kDa non-glycoprotein from M.
paratuberculosis. Moreover, this is the first study which reports that the zoonotic M.
paratuberculosis supports posttranslational modification similar to M. tuberculosis and
M. leprae pathogens. Although the posttranslational modification component in this 19
kDa nonglycoprotein did not affect T- cell response, the finding is significant toward
glycoproteins from M. paratuberculosis and their role in the pathogenesis of this bacterial
infection in animals and humans.
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CHAPTER ONE
INTRODUCTION
Most members of the genus Mycobacterium are important pathogens of humans and
animals. In humans, leprosy and tuberculosis (TB), caused by Mycobacterium leprae and
Mycobacterium tuberculosis, respectively, continue to be serious public health problems
and leading causes of death world-wide. The incidence of leprosy is 15 million worldwide, with approximately 30% of its victims suffering severe disfiguration (37, 21).
Tuberculosis is a highly contagious disease with over 8 million new cases and 3 million
fatalities occurring annually as estimated by World Health Organization (WHO) (1, 4, 11,
31). The synergy between HIV and TB, combined with the emergence of multidrugresistant strains of M. tuberculosis in several parts of the world has fueled fears of the
spread of TB in the near future (1,2) M. avium complex (MAC) causes disseminated
diseases especially in persons with AIDS (60). Nair et al. (1992) reported that 50% of
individuals with AIDS develop MAC disease symptoms. M. paratuberculosis, the
causative agent of Johne’s disease, causes enormous economic loss in the dairy industry
(8, 62, 28). In the United States, prevalence studied has estimated that between 20 to 30%
of dairy herds are infected with M. avium subsp. paratuberculosis as a result over $200
million in lost annual revenue to the dairy industry (10, 28, 61).
M. paratuberculosis has been proposed to be associated with Crohn’s disease, a painful
debilitating chronic inflammatory bowel disease of the GI tract following the
identification of this bacterium in intestinal tissue from Crohn’s disease patients (40, 52).
The association has been vigorously debated in recent years especially following the
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consistent isolation of M. paratuberculosis from tissue, milk and blood from humans with
Crohn’s disease (53, 42, 9, 43, 54).
Although drug therapy can be effective against some mycobacterial infections, vaccines
offer the best hope of controlling these diseases and eliminating their agents.
Development of vaccines and improved therapies and diagnostic methods will require a
more basic understanding of mycobacterial antigens and their encoding genes. Small
quantities of immunogenic proteins identified in mycobacterial cultures, slow growth of
pathogenic mycobacteria (M. tuberculosis, M. paratuberculosis) or not at all (M. leprae)
in laboratory, and safety precautious needed to work with pathogenic bacteria are some of
the barriers that make difficulties in evaluating of these antigens (27). The development
of recombinant protein technology to express important genes in E. coli has been well
established. However, limited success has been reported following attempts to express
some mycobacterial genes in E. coli cloning expression system. The variability in the
%G+C content and the nature of the mycobacterial cell wall between E. coli and
Mycobacterium may contribute significantly to the variation. Additionally, recent studies
have shown some post-translational modifications in mycobacterial antigens such as
acyaltion and glycosylation (20, 25), which is lacking in the majority of Gram negative
bacteria such as E. coli. Consequently, expression of some mycobacterial proteins in E.
coli expression system, may lead to expression of limited quality and nature of cloned
genes. There is great need for cloning mycobacterial genes and expression of encoding
antigens in a homologous host which may provide as an alternative for expression of
proteins similar to those from the native host (59, 27). Therefore, performing these
manipulations in a homologous host has the advantage of permitting possible
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posttranslational pathways that may include immunomodulatory components. For
example, it has been found that functionally active superoxide dismutase was expressed
by mycobacterial system, in contrast to the enzymatically inactive protein produce in E.
coli (63). Another example showed decreasing capacity of E. coli recombinant 45/47-kDa
molecules (Apa) of M. tuberculosis to stimulate T lymphocyte responses (27).
The first attempt to achieve that was initiated by constructing a chimeric shuttle plasmid
containing a mycobacteriophage DNA inserted into an E. coli cosmid (29). This shuttle
plasmid replicated in E. coli as a plasmid and in mycobacteria as phages. This was
followed by construction of many shuttle plasmids derived from the M. fortuitum plasmid
pAL5000 (33). Most of these shuttle plasmids were characterized by their large size and
lacked sufficient genetic elements. Consequently, the introduction and expression of
foreign genes and their encoding products in mycobacteria requires use of efficient
shuttle plasmids.
M. paratuberculosis continues to emerge as significant pathogen to humans with
Crohn’s disease and animals with Johne’s disease. Understanding virulence mechanism
in this bacterium will aid in understanding its pathogenesis and ultimately controlling it.
In this study, we attempt to investigate M. paratuberculosis for its ability to support
posttranslational modification. Ultimately more questions need to be answered
concerning the role of such modification in this important pathogen. In this laboratory, a
previously constructed genomic library of M. paratuberculosis in E. coli revealed the
identification of the Clone pMptb #28 containing 4.8 kb insert and the expression of a
single 16 kDa protein product. When the 4.8 kb was cloned in M. smegmatis using
pNEZ6.3 shuttle plasmid, the expressed product was estimated at 19 kDa similar to the
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size present in M. paratuberculosis. The main objective in this study is to identify the
ORF nucleotide sequence of the encoding gene followed by cloning it in E. coli and M.
smegmatis. The outcome of this study will determine weather M. paratuberculosis
supports posttranslational modification or not. If it does this, the nature of the
posttranslational medication would be investigated for possible glycosylation and its role
in the antigenicity of the protein against T-lymphocyte derived from Crohn’s disease
patients and normal controls.
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CHAPTER TWO
MATERIALS AND METHODS

Bacterial Strains and Growth Conditions
E. coli strain TOP10 purchased from Invitrogen (Invitrogen Corp., Carlsbad, CA) and its
recombinants were grown in Luria Britani (LB) broth media (1% w/v tryptone, 0.5% w/v
yeast extract and 1% w/v NaCl) supplemented with ampicillin and/or kanamycin (Sigma)
0

at a final concentration of 50ug/ml. The 2 ml starting cultures were incubated at 37 C
with agitation at 175 rpm for 16 hours until OD

600

achieves 1.2 to 1.5. The overnight

culture was further transferred and grown in the large volume of LB broth in the similar
condition. The E. coli clone containing the plasmid pMptb#28 was obtained from our
genomic library as described previously (15).
M. smegmatis mc2155, an efficient plasmid transformation mutant of M. smegmatis
strain ATCC 607 isolated by Snapper et al. (1988), was obtained from Dr. Charlotte
McCarthy (Department of Biology, New Mexico State University, Las Cruces, NM). M.
paratuberculosis strain linda (ATCC 43015), a clinical strain isolated from a Crohn’s
disease patient by Chiodini et al. (1984) was obtained from Dr. P. Brennan (Department
of Microbiology, Colorado State University, Fort Collins, CO). They were grown in
Middlebrook 7H9 broth supplemented with OADC enrichment (Difco Laboratories,
Detroit, MI), 0.5% glycerol and 0.05% Tween 80 (Sigma Chemical Co., St. Louis, Mo).
Mycobactin J (Allied Monitor Inc., Fayette, Mo) was added to the broth for culturing M.
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paratuberculosis at 2 mg/L as described by Graham et al. (1987). The inoculated broth
was incubated at 37 °C on a rotary shaker (150 rpm) until an optical density OD

600

of 1.8

(48 hours for M. smegmatis and 4-6 weeks for M. paratuberculosis). M. smegmatis
kanamycin resistant recombinants were isolated on 7H10 agar plates supplemented with
OADC, glycerol (0.5%v/v) and 50 ug/ml kanamycin. An E. coli clone containing the
shuttle plasmid pAL32 (Labidi et al., 1985) was obtained from Labidi (Cytogenetics
Vaccine Co., Dallas, TX).

Shuttle Plasmid Construction
The shuttle plasmid pNEZ6.3 used in this study was previously constructed by Naser et
al. (1996). The ori of pBR322 is located upstream of Sp6 promoter whereas the f1 ori is
located upstream of the T7 promoter. In addition, it contains the ori of pAL5000 and the
Kan resistant gene(Km). The shuttle plasmid Pmip12 (6800bp), was also used in this
experiment (36). It carries the pAL5000 origin of replication, promoter derived from
mycobacterium fortuitum, and Kan resistance gene (36).

Plasmid DNA Extraction
Plasmid DNA from M. smegmatis and kanamycin resistant recombinants was prepared
following a modification of that described by Kado and Liu, 1981 (32). Briefly, the cell
pellet from 30 ml of culture broth was suspended in 2.0 ml TE (10 mM Tris-Cl, 1 mM
EDTA, pH 8.0), mixed with lysozyme (50 mg/ml) and then incubated at 37°C on a rotary
shaker (100 rpm) for 18 hours. Four ml of lysing buffer (3% SDS, 50 mM Tris-Cl, pH
11.7) was added, mixed and then incubated at 68°C for 30 min. The lysate was extracted
with phenol:isoamyl alcohol chlorofrom (1:1, v/v) and then precipitated with ethanol.
Plasmid DNA from E. coli was prepared by Qiagen (QIAGEN Inc., Chatsworth, CA) as
17

described by the manufacturer. The extracted plasmid DNA was further digested with
restriction endonuclease at 37ºC for 2-3 hours. Then, digested plasmids were analyzed by
Agarose Gel Electroforesis to observe the size of plasmid and insert. To verify the
nucleotide sequence of insertion, samples were sent to the DNA sequencing.

SDS- Ployacrylamide Gel Electrophoresis and Silver Staining
SDS-PAGE was performed using the Mini-protein II Dual slab cell unit according to
manufacturer’s instruction. Discontinuous polyacrylamide gels (12% w/v separating and
4 % w/v stacking gels) were prepared. Following electrophoresis, gels can be silver
stained to visualize bands. Gels were first fixed with fixative solution I containing 40 %(
v/v) methanol and 10% (v/v) acetic acid for 30 min at room temperature followed by two
15 min incubations with fixative solution II which consists of 10% (v/v) ethanol and 5%
(v/v) acetic acid. Gels then were incubation with 50 ml of 10 %( v/v) potassium
dichromate and nitric acid containing oxidizer (BioRad) for 2 min and rinsed with
Millipore water until cleared. After incubated with 50 ml of 10% (v/v) silver nitrate
containing silver reagent for at least 30 min and rinsed twice with Millipore water, gels
were developed with 100ml of 3.2% (w/v) silver stain developer including carbonate and
paraformaldehyde. When the bands reached the desired density in relation to background,
the reaction was stopped by 5% acetic acid.

Immunoblotting
The protein extracts of M. paratuberculosis, M. smegmatis and the kanamycin resistant
recombinant clones were prepared by sonication and estimated following standard
procedures (14, 15). The protein content of E. coli and the sonicate of mycobacterial
cells were solubilized by boiling for 15 min in an equal volume of SDS-gel sample buffer
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(Tris.Cl, pH 6.8, 2.5% SDS, 100 mM DTT, 10% (v/v) glycerol and 0.02% (w/v)
bromophenol blue). The extracts were centrifuged for 15 min and the supernates were
fractionated on 12% SDS-PAGE. A prestained protein molecular weight standard (BioRad) was included in each SDS-PAGE gel, which were followed by transferred onto
nitrocellulose membrane (Bio-Rad transblot medium) using a Bio-Rad Trans blot mini
electrophoretic chamber (120 V, 80 A for 1 hour). Immunoblot filters containing
fractionated proteins were blocked with 10% non-fat milk in tris-phosphate buffered
saline (PBS) buffer at either 4°C overnight or room temperature for at least 3 hours. The
membrane was washed with PBST twice for 5 minutes each and then incubated with
rabbit hyperimmune anti-M. paratuberculosis serum (1:10,000) at 4°C overnight with
gentle agitation. The membrane was again washed twice with PBST and incubated with
1:10,000 diluted Goat anti-rabbit IgG-peroxidase conjugates. After similar washes signal
on the membrane can be visualized by adding opti-4CN diluent solution substrate (BioRad). Following color development, filters were washed in distilled water and air-dried.

Unidirectional DNA deletion Exonuclease III
Purified pMptb#28 was digested with XbaI (Promega, Madison, WI) as described by the
manufacturer. The recessed ends were filled in with α-phosphothiorate nt (Promega) and
DNA polymerase as described by Sambrook et al. The sample was then digested with
SpeI (Promega) to generate a 5’ overhang closest to the insert, followed by phenol
chloroform extraction and sodium acetate precipitation (51). The sample was added to an
exonuclease buffer (0.66 mM Tris/Cl(PH 8.0), 66mM MgCl2) and incubated at 37ºC for
5min. ExonucleaseIII(2.5U) was added and 2.5ul aliquot were removed every 30 sec,
mixed with 75ul of ice cold S1 reaction mixture (3mM potassium acetate, PH 4.6, 2.5mM
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NaCl, 0.1 M EDTA and incubated at 50ºC for 10min. DNA deletion was estimated by
agarose gel electrophoresis (51). Re-circularization of new plasmids was done by T4
DNA Ligase (Promega) and transformation into E. coli TOP10 competent cells was
performed by electroporation. Colonies were screened for smaller plasmids and
subclones of pMptb#28 were isolated. For sequencing, each transformed colony was
grown and plasmid DNA was isolated by use of Qiagen Midi Kit (QIAGEN). The T7
universal primer or Sp6 primer was used to sequence the inserts of the subclones.
Immunoblotting was followed to check for producing the protein.

Construction of E. coli Subclone (EB486)
The sequence of 486 bp Opening Reading Frame producing19kDa hypothetical protein in
Mycobacterium paratuberculosis according to data base, was blasted to the sequence of
4.8kb insertion. After finding the area, the sequence of 486 bp was amplified and cloned
to pBAD system as will describe in detail.

The Cloning System
The pBAD/His is a pUC-derived expression vector purchased from Invitrogen. It is
designed for regulated, dose-dependent recombinant protein expression and purification
in E. coli. The regulatory protein, AraC, was provided on the pBAD/His vector allowing
regulation of pBAD. In the presence of arabinose, expression from pBAD was turned on
while the absence of arabinose produces very low levels of transcription from pBAD. By
varying the concentration of arabinose, protein expression levels could be optimized to
ensure maximum expression of soluble protein. The plasmid pBAD/His is a 4.1 Kb
prokaryotic expression vector. It has the following features: the pBAD promoter and the
araC gene product for regulated expression of the gene of interest, N-terminal
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polyhistidine tag for rapid purification of fusion proteins using ProBond™ resin, antiXpress™ epitope for detection of fusion proteins with the Anti-Xpress™ Antibody,
enterokinase cleavage site to facilitate removal of the fusion protein, multiple cloning site
in three reading frames to simplify subcloning in frame with the N-terminal polyhistidine
tag, and ampicillin resistance gene and ColE1 origin for selection and maintenance in E.
coli.

Oligonucleotide Primers design
According to the nucleotide sequence of on data base, a pair of oligonucleotide primers
Forward and Reverse, including restriction recognition sites for Bgl II and EcoR I were
designed to amplify exactly 486bp sequence.

Table 1: The Sequence of Primers Used in Construction of EB486
Subclone
Primers sequence

Target

F 5’-CACCAG ATCTTCAGCTGT TGCAGGT -3’

Clone28

Tm(ºC) Product
59

506bp

R 5’-CCACGA AATCGTGAAGCGTCAACTG-3’

Polymerase Chain Reaction (PCR)
The PCR reaction was performed in a total volume of 50 ul containing PCR reaction
buffer, 3M Betaine , MgSO4 solution at a final concentration of 50mM,10 mM of
deoxynucleotides (dATP, dCTP, dGTP, dTTP); 3ul of each set of the primers; 1 unit of
High Fidelity Taq DNA polymerase; and 1 ul volume DNA template of pMptb#28
plasmid carrying 4.8kb fragment. The reaction mixture was subjected to 30 cycles of
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amplifications performed in a programmable thermal controller, as follows: 5 minute
denaturation at 95°C, denaturation at 94°C for 45 seconds, 30 second annealing at 56°C;
and 1 min primer extension at 72°C. After the 30 cycles, reactions were extended for 10
min at 72°C.

Purification of Amplified PCR DNA Product
In order to clean up the impurities, including primer dimmers, non-specific amplification
products and templates, the PCR amplified DNA was purified by Wizard PCR Preps
DNA Purification system (Promega). The PCR products were first separated by
electrophoresis on 1% (w/v) low melting agarose gel (Fisher Scientific). The excised gel
slice (around 300mg) was transferred to 1.5 ml microcentrifuge tube and heated at 70 °C
until the agarose was completely melted. 1 ml resin was then mixed with melted agarose
thoroughly and slowly passed through the minicolumn by 3-ml syringe. After washed
with 2ml 80% isopropanol, DNA was eluted out with 50 ul sterile water at 9,600 rpm for
1min. Cleaned PCR product was further confirmed by sequencing.

Restriction Enzyme Digestion
Both pBAD/His plasmid and amplified DNA were digested by restriction endonucleases
enzymes of Bgl II and EcoR I. Then, the digested plasmid pBAD/His was
dephorsphorylated by Shrimp alkaline phosphatase (SAP, Promega) for 1 h at 37°C to
prevent self ligation. The shrimp alkaline phosphatase was inactivated by heating for 10
min at 70°C.
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Ligation
The dephosphorylated pBAD/His vector (50 ng) was then ligated to an EcoRI and Bgl II
PCR digest using T4 DNA ligase (Promega) following standard procedure. Using a ratio
of 1:3 for the vector to genomic DNA digest, the ligation mixture was incubated at 16 °C
overnight. As a control, a tube containing dephosphorylated pBAD/His vector only was
treated under the same conditions.

Electroporation in E. coli
The mixture of ligated pBAD/His and digested amplified product was transformed into
E. coli TOP10 competent cells by electroporation as described by Sambrook et al.
Electroporation was performed using the Gene Pulser and Pulse Controller instruments
from Bio-Rad (Bio-Rad Laboratories, Richmond, CA). A volume of 2 ul of the ligated
DNA was mixed with 50 ul of electrocompetent E. coli TOP10 cells. It was placed on ice
for few minutes and then the cells were transferred into an ice cold 0.2 cm electrode
chamber (electroporation cuvette). Electroporation was performed at 1.75 KV, 200
(ohms), and 2.5uF using the standard setting. The electroporated cells were suspended in
0

1.0 ml of SOC medium, incubated for 1 hr at 37 C, and then spread onto LB agar plates
0

containing ampicillin (50 ug/ml). The plates were incubated at 37 C for overnight.
pBAD/His vector was transformed under the same conditions as a positive control. The
colonies were further screened and verified by Cell Pop PCR described later.

Verification of EB486 Cloning using Cell Pop PCR Method
The PCR reaction was performed in a total volume of 25 ul containing PCR reaction
buffer, 3M Betaine , MgSO4 solution at a final concentration of 50mM,10 mM of
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deoxynucleotides (dATP, dCTP, dGTP, dTTP); 1.5ul of each set of the primers; 0.5 unit
of High Fidelity Taq DNA polymerase; the colonies were randomly picked from the agar
plate by sterile toothpick and directly served as DNA template without DNA extraction.
The reaction mixture was subjected to 30 cycles of amplifications performed in a
programmable thermal controller, as follows: 15 minute denaturation at 95 °C,
denaturation at 94°C for 45 seconds, 30 second annealing at 56 °C; and 1 min primer
extension at 72 °C. After the 30 cycles, reactions were extended for 10 min at 72 °C. The
amplified products were visualized by agarose gel electrophoresis.

Screening of EB486 for protein expression
The PCR positive subclones were grown, induced with L- Arabinose and harvested as
described before. Each cell pellet resuspended in 25 ul of sterile deionized water and 75
ul sample buffer were solubilized at 95◦C for 15 minutes and fractionated on 12% SDSPAGE gel followed by transferred onto nitrocellulose membrane (Bio-Rad transblot
medium) at 4°C for 12-16, voltage of 40V using a Bio-Rad lectrophoretic chamber.A
prestained protein molecular weight standard (Bio-Rad) was included in each SDSPAGE. Immunoblot filters containing fractionated proteins from recombinant E. coli
0

were blocked with 1% BSA in PBST buffer at either 4 C overnight or room temperature
for 3 hours. Then the membrane was incubated with anti-His or anti-Xpress™
0

monoclonal antibody (Invitrogen) (1:4000) at 4 C overnight with gentle agitation. The
membrane was followed by incubating with1:4000 diluted Goat anti-mouse IgGperoxidase conjugates. The signals on the membrane can be visualized by adding opti4CN diluent solution substrate (Bio-Rad)
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To optimize overexpression of recombinant protein, the recombinant colony was
inoculated and grown in Laura Britani (LB) broth media containing 50 ug/ml ampicillin
at 37 °C with agitation at 175 rpm until OD

600

equals 1.5. The 100ul overnight culture

were then transferred to each 10ml LB broth and grown in the same condition until OD

600

was 0.5. A serial dilution of L-arabinose (Becton Dickinson, Sparks, MD) at a final
concentration from 0.0002% to 2% was added into each 10 ml culture and 1ml sample
was taken every two hours from each tube. The aliquot of cells from each tube was
centrifuged at 12,000rpm for 2 minutes and kept frozen at -20 °C for further analysis by
immunoblotting as describe earlier.

Purification of Recombinant Protein
6x His-tagged fusion proteins were purified by using B-PER 6xHis Spin Purification Kit
(PIERCE Biotechnology) with some modification as manufacturer described. The
bacterial cell pellet from a 250ml culture (OD

600

= 1.5.-3.0) was re-suspended in 10ml B-

PER reagent by vortexing until the cell suspension was homogeneous. The homogenous
mixture was gently shaken at room temperature for 10min. The separation of soluble
from insoluble proteins was followed by centrifugation (14000 rpm, 15min) at 4°C in
autoclaved, high-speed centrifuge tubes. The supernatant (soluble fraction) was
transferred to a 15 mL capped conical centrifuge tube; a small sample was reserved for
immunoblot analysis. The pellet was also stored as the insoluble fraction. The NickelChelated Agarose was equilibrated at room temperature and 1 mL of the 50% gel slurry
was added to the soluble fraction, and was incubated for 10 minutes at room temperature,
then centrifuged at 6,000 rpm for 10 minutes at 4°C. The supernatant was removed and

25

stored at -80°C as Flow Thrugh and the resin was re-suspended with 0.25 mL of Wash
Buffer, also equilibrated at room temperature. The gel-bound, 6x-His fusion protein was
transferred to the Microfilter Spin column and centrifuged for 3 minutes at 10,000 rpm at
4°C. The Microfilter spin column was transferred to a new autoclaved collection tube
after each centrifugation. The agarose slurry was re-suspending in 0.5 mL of wash buffer
and centrifuged at 10,000 rpm for 3 minutes following an incubation of 5 minutes.
During the incubation, the collection tube gently tapped to re-suspend the slurry, and
column was washed 5 more times. All the washes were collected in separate collection
tubes: Wash1-Wash6. The resin was transferred to a new Microfilter Spin column and
was incubated in 0.5 mL of Elution Buffer for 5 minutes, followed by centrifugation at
12,000 for 3 minutes. This step was repeated 4 more times and the samples were
collected into separate collection tubes: Eluted1-Eluted5. All the fractions were stored at
-80°C for further analysis.

Construction of M. smegmatis Subclone (SM486)
In order to clone the sequence of 486 bp Opening Reading Frame producing19kDa
protein to Mycobacterium smegmatis, an E. coli mycobacterium shuttle vector, Pmip12,
was used in this experiment (36). The sequence 486 ORF was amplified and ligated to
Pmip12 shuttle vector and transformed in E.coli top 10 competent cells and then
transformed to M. smegmatis mc2155 competent cells as will describe in detail.
According to the shuttle vector map, two different restriction enzymes, BamH I and Kpn I
were chosen to use for directional ligation. Therefore, a set of two primers were designed
to amplify the 486 bp of ORF sequence.
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Table 2: Sequence of Primers Used in Construction of SM486 Subclone

Primers sequence

Target

Tm

Product

(ºC)
F-5’ATCGGGATCCGTGAAGCG TCA ACTGACGATC3’

Clone28

64

506bp

R-5’ATCGGG TACCTCAGCTGTTGCAGGTCACATC3’

Cloning the Plasmid Construct into E. coli (The Transition Step)
PCR was performed by using the oligos as mentioned before. Then PCR product and
shuttle vector were digested with BamH I and Kpn I restriction enzyme and ligation
procedure was preformed as described earlier. Electropration to E. coli TOP 10
competent cells, screening the subclone by Cell Pop PCR, and confirming the right
Subclone by plasmid extraction was achieved as previously stated.

Preparation of M. smegmatis mc2155 Competent Cells
One single colony of M. smegmatis mc2155 was inoculated in 2ml Middlebrook 7H9
broth supplemented with OADC enrichment (Difco Laboratories, Detroit, MI), 0.5%
glycerol and 0.05% Tween 80 (Sigma Chemical Co., St. Louis, Mo) at 37° C with
constant shaking. After 2 days, 2 ml were transferred to 20 ml of the same media, and
again after 2 days 20 ml were transferred to 1 liter of the media and incubate until OD

600

achieves 0.2 to 1 in 2 days. Then it was incubated on ice for 1.5 hours before harvesting.
The cells were harvested in 250ml centrifuge bottles by spinning for 10min at 5,000 x g
at 4° C and the supernatant was discarded. The pellet was resuspended in an equal
volume (250ml) of 10%glycerol, and centrifuge again. The next was resuspending each
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pellet in 10ml ice-cold 10%glycerol, combining cells and transferring to two 50ml tubes.
The volume of each tube was brought to 50ml with ice-cold 10%glycerol and centrifuged
for 10min at 2,000 x g at 4° C. The pellet was re-suspended in 50ml ice-cold
10%glycerol and then centrifuged as above for 15min. Each of the two pellets was resuspended in 10%glycerol for a final volume of 1ml. At this time, cells were aliquot
about 100ul into 1.5ml sterile tube and stored at -80°C to use later

Electroporation of M. smegmatis Competent Cells
M. smegmatis mc2155 cells were prepared for electroporation following the procedure as
described earlier by Jacobs et al.(1991). Electroporation was performed using the Gene
Pulser and Pulse Controller instruments from Bio-Rad (Bio-Rad Laboratories, Richmond,
CA). The electroporated cells were suspended in 1.0 ml of Middlebrook 7H9 broth
supplemented with OADC enrichment, 0.5% glycerol and 0.05% Tween 80, incubated at
37 C with agitation (150 rpm) for 2 h, and then spread onto 7H10 agar with 50 ug/ml
kanamycin. The plates were incubated at 37 C and colonies were counted after 72 h.

Bioinformatics Analysis
In this study some bioinformatics software used are including: Blast analyses, ORF
finder, Oligonucleotide Properties Calculator, Primers design, and Expasy Proteomics
tools for protein identification and characterization.
http://www.ncbi.nlm.nih.gov/BLAST/
http://bioinformatics.org/sms/orf_find.html
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi
http://www.bioinfo.rpi.edu/~zukerm/
http://www.basic.northwestern.edu/biotools/oligocalc.html
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http://www.expasy.org/tools/

Purification of Recombinant Proteins from Polyacrylamide Gels
Purification of expressed proteins from E. coli and M. smegamatis hosts were performed
following standard procedures (51, 15). Initially two SDS gels loaded identically with
samples from marker and bacterial cells were prepared. One gel was stained with silver
stain following standard procedure as described earlier. Protein bands with size of
interest were identified and then lined up with the second unstained gel. Portion of the
gels with bands of interest were cut, transferred to sterile tubes and then incubated with
elution buffer. The remained unstained gel was then stained with silver stain in order to
confirm the excision of the correct part of the gel. The excised gel pieces placed in sterile
microcentrifuge tube was covered with elution buffer (50 mM Tris-HCl, 150 mM NaCl,
and 0.1 mM EDTA; pH 7.5) and incubated in a rotary shaker at 30 °C for overnight. The
supernatant was transfers to new tube following centrifugation 10,000 × g for 10min.
Aliquots of eluted protein were then confirmed by sliver stain and with rabbit anti-MAP
IgG antibodies.

Carbohydrate analysis:
Due to the variation in the size of the expressed protein in lystaes from E. coli and M.
smegmatis recombinant cells which may be due to posttranslational modification, we
sought to investigate whether the modification of the protein is due to glycosylation or
something lese. Evaluation of the protein for glycosylation was performed by ConA
staining and by the use of deglycosylation enzymatic assay.
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A: ConA Staining
The procedures for staining of nitrocellulose blots with peroxidase-conjugated
concanavalin A (ConA) were basically identical to those used for immunobloting as
described earlier. Nonspecific binding was blocked by incubating blots at either 4 0C for
overnight or at room temperature for at least 3 hours with 4% (wt/vol) BSA in phosphatebuffered saline (PBS) with Triton X-100 (0.2%, vol/vol). Following several washes with
PBS and PBS-Triton X-100, the blots were incubated with 20 ml of ConA-peroxidase
conjugate (0.2 purpurogallin units per ml;Sigma) in 2% (wt/vol) BSA in PBS-Triton X100 for 4 0C for overnight or at room temperature for 5-7 hours as described by the
manufacturer. Following several washes washes, the membrane was developed and
evaluated for glycosylation using opti-4CN diluent solution substrate (Bio- Rad).
B: Enzymatic Protein Deglycosylation assay
Enzymatic analysis for the presence of glycoprotein in the samples was performed using
Deglycosylation kit purchased and following instructions provided by the manufacturer
(EDEGLY Sigam-Aldrich). Briefly 10ul of 5x Reaction Buffer and 2.5ul of Denatuation
Buffer were added to 35 ul of bacterial cell extracts including 100mg or less of protein
and then heated at 1000C for 5min. After cooling at room temperature, 2.5ul of TRITON
X-100 solution was added to each sample, and followed by adding 1 µl each of the
PNGase F, O-Glycosidase, α-2(3, 6, 8, 9) Neuraminidase solutions, β (1-4)Galactosidase,
and β−N-Acetylglucosaminidase. The mixtures were incubated for 3 hours at 37 °C, and
then analyzed by similar Staining or Immunoblot. Bovine fetuin was supplied as a control
glycoprotein since it contains sialylated N-linked and O-linked oligosaccharides
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Evaluation of Expressed protein for Antigenicity
The variation in size for the expressed protein originated from E. coli and M. smegmatis
recombinant clones hinted to us to investigate for the presence of any immunomoldilatory
interference. Initially, the same protein from the two different hosts was evaluated against
rabbit anti-MAP IgG antibodies. Then the proteins were also evaluated against T- cells
from two healthy individuals and two patients with Crohn’s disease.

Source of Lymphocytes
In this study, mononuclear cells (mostly T lymphocytes) originated from two individuals
that were considered healthy controls and two patients with confirmed Crohn’s disease
diagnosis. Blood cells were collected in EDTA-tubes and transported to the lab within 24
hours. Immediately, the blood samples were processed for isolation of peripheral blood
mononuclear cells (PBMNC’s) and then used in T-cell proliferations assays.

Isolation and Quantitation of Human PBMCs
PBMC were isolated using lymphoprep density gradient separation medium following the
manufacturer’s procedure (Greiner Bio One, Inc). Fresh 5ml blood sample were
immediately processed in a Biosafety Cabinet Class II as follows: First, blood samples
were diluted 1:1 (v/v) by RPMI culture media (Invitrogen, CA) at room temperature. And
then, a volume of 4mL of diluted blood was layered on 4mL Lymphoprep solution in
15mL polypropylene tubes. Tubes were centrifuged at 1,550 rpm in room temperature for
30 min. As a result of centrifuge, the density gradient interface forms, this was followed
by transferring the white band containing PBMCs to a sterile tube. Hemocytometer
counting was used to determine the PBMCs concentration.
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T-Cell Proliferation Assay
5

Isolated PBMC adjusted at final concentration of 1 x 10 cells/ well in RPMI 1640, and
were mixed with 10% plasma. T- cells were then evaluated against mitogen controls
including PHA (phytohemmatoagglutinin) and PWM (Polkweed mitogen). PPD from
MAP was prepared in our lab and was also used. Additionally protein lystates from
recombinant E. coli and M. smegamtis were used in this assy. The cell extracts of E. coli
and M. smegmatis and MAP PPD were prepared by sonication of cell pellets from
cultures grown (approximately six weeks for MAP, 2-3 days for M. smegmatis and 1day
for E. coli) followed by centrifugation at 16,000 rpm for 30 m, Cell debris were discarded
o

and supernatants were transferred to sterile tube and stored at -80 C until use. Protein
content was measured in each sample following Bradford method. (6)
Initially, in order to determine the optimal concentration, bacterial extracts (E. coli and
M. smegmatis) and MAP PPD were added to triplicate wells at different concentration of
2, 20, 40, 80 ug/ml. The plates were then incubated at 37 °C in a humidified air with 5%
CO2 incubator during 3 days. The proliferation assay was followed by labeling the
PBMC with bromodeoxyuridine (BrdU, Roche Molecular Biochemicals, IN) and
reincubated for additional 24 h, and cell transformation was then measured using cell
proliferation ELISA BrdU commercially available kit from Roche ((Indianapolis, IN).
Briefly, BrdU was taking up by DNA of the cells while they were dividing and then was
measured by using a monoclonal antibody, anti-BrdU-POD, conjugated with peroxidase.
The immune complexes were detected by a substrate reaction and the reaction product
was quantified by measuring the absorbance at 492nm in an ELISA Auto Reader II
(Ortho Diagnostic Systems, Inc). The positive controls with the optimal concentration
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were including: PHA (20ug/mL, Sigma, MO), PWM, pokeweed mitogen, (10ug/ml
Sigma, MO), and MAP purified protein derivative (PPD; 5ug/mL). The cells only were
used as negative control.
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CHAPTER THREE
RESULTS
Preliminary data for Clones pMptb#28 and Smeg19k
Previously in our lab, a genomic library of Mycobacterium avium paratuberculosis was
constructed in E. coli. Colonies were screened for gene expression using immunoblot and
rabbit anti-M. paratuberculosis antibody. Clones specific to M. paratuberculosis were
identified when they reacted negatively with rabbit anti-M. tuberculosis, rabbit anti-M.
leprae and rabbit anti-M. bovis and rabbit anti-M. avium subspecies avium antibodies.
pMptb#28 recombinant clone contained the insert of 4.8 kb and encoded for a single
protein of 16kDa. Surprisingly, M. paratuberculosis lacked a 16 kDa protein band when
screen with rabbit anti-M. paratuberculosis antibodies. When the 4.8 kb BamH I
fragment was cloned in M. smegmatis using a shuttle plasmid, it produced a 19 kDa
protein (Smeg19k) similar to the size observed in extracts from M. paratuberculosis.
These preliminary data were collected earlier in our lab.

Confirmation of the Identity of Clones pMptb#28 and Smeg19k Plasmids
In order to confirm the identity of the clones pMptb#28 and Smeg19k, both clones were
inoculated from stock culture and then cultured in LB with ampicillin and 7H9 with
kanamycin, respectively. Cell pellets were analyzed at both the DNA and protein levels.
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DNA Level:
DNA extracted clones pMptb#28 and Smeg19k were digested with BamHI restriction
endonuclease enzyme. The presence of 4.8 kb insert on 1% agarose gel is shown in
Figures 1 and 2.
Protein Level:
Protein extracts from pMptb#28 and Smeg19k clones and from M. paratuberculosis, M.
smegmatis transformed with pNEZ6.3 shuttle plasmid and E. coli with pcDNAII plasmid
were screened by immunoblot using E. coli adsorbed rabbit anti-M. paratuberculosis
antibodies. As shown in Figure (3), a 16kDa protein band was detected in the pMptb#28
(lane 5) compared to a 19kDa protein band detected in the protein extracts from Smeg19k
clone (lane 3) similar to the native size detected in the M. paratuberculosis protein
extract (lane 2). There was no reactivity in extracts from the hosts, E. coli (lane 6) or M.
smegmatis (lane 4) without the insert.

Identification of 16/19 kDa Encoding Sequence (ORF):
By DNA Nested Deletion:
The 4.8 kb insert was evaluated and analyzed for the presence of the possible ORF
encoding the 16/19 kDa expressed protein. Initially the 4.8 kb insert was sequenced from
both ends (the 5’ and 3’) but since the MAP genome sequence was not published yet,
alternative methodology were used in attempt to identify the ORF. Consequently, DNA
nested deletion (Gene Walking) was employed. Following unidirectional deletion of
linearized pMptb#28 by ExonucleaseIII, minilibrary of subclones were screened with
rabbit anti-M. paratuberculosis antibody. The goal was to find a subclone with the
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smallest plasmid that still able to produce the 16kDa protein in E. coli. As shown in
Figure (4), the size of the plasmid is getting smaller with increased exposure to
Exonuclease. Some of these plasmids were selected and relegated then transformed into
E. coli TOP10 competent cells. .Subclones were examined for expression of 16 kDa
protein. As shown in Figure 5, some subclones expressed the expected 16 kDa protein
and others did not. The subclones were analyzed for determination of plasmid size.
Figure 6 illustrates that subclone #4contained the smallest insert (2.5 kb) which continued
to the16kDa protein.
By Nucleotide Sequencing:
The extracted plasmid from subclones #4 and #5 were analyzed by sequencing.
Nucleotide sequences from the 5’ and 3’ ends of the two subclones and the release of the
M. paratuberculosis genome sequence at this time have enabled us to identify the region
on the 4.8 kb insert which may encode for the expression of the 16/19 kDa protein. Blast
analysis of the identified sequence region with the data base has produced identity with a
19 kDa protein from M. bovis and M. leprae. Accordingly, we were able to identify the
start codon and the stop codone of the possible ORF consisting of 486 bp.

Construction of Subclone EB486 (E. coli Subclone)
Given that the unidirectional exonuclease technique was capable of eliminating some
additional sequences that are unrelated for the expression of 16/19 kDa protein, the
technique was insufficient for identifying the exact open reading frame that codes for the
protein. Therefore it was required to find the exact ORF of the protein, and then to
expresses in E. coli and M. smegmatis to able to do further characterization. The 486bp
sequence of ORF was identified using bioinformatics software. Oligonucleotide primers
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with cloning enzyme sequence for Bgl II and EcoR I were designed and the possible ORF
was amplified using PCR technology from pMptb#28 DNA template. The PCR product
was purified, ligated to pBAD/His expression plasmid vector and then transformed into
E. coli competent cells. As shown in figure (7), the expected size of 506 bp PCR product
was detected on 2% agarose gel. Controls with templates from pcDNAII were negative.
The amplified ORF was further confirmed through nucleotide sequence analysis. The
amplified ORF sequenced was purified and then ligated into dephorphorylated pBAD/His
plasmid and then electroporated into TOP 10 E. coli competent cells. Ampicillin resistant
colonies were analyzed for the presence of the insert and the expression of encoding
product.

Identification of Recombinant Subclone EB486
Three ampicillin resistant colonies were picked, subcultured and then analyzed for the
presence of the 486 bp ORF sequence and the expression of 16/19 kDa protein. As
shown Figure (8), all three colonies were positive by Cell Pop PCR, PCR product was
purified and sequenced and was confirmed to contain the expected 486 bp sequence.
Extracted plasmid from positive colonies were further digested with both enzymes, Bgl II
and EcoR I, and then analyzed on agarose gel. As shown in Figure (9), the insert with an
estimated 486bp was observed. The three colonies were inoculated in LB broth and
induced by L-arabinose to express the fusion protein, which were further examined by
immunoblot using anti-His antibody, anti-Xpress antibody and E. coli adsorbed rabbit
anti-M. paratuberculosis antibody. As shown in Figures 10, 11 and 12, all colonies
expressed 22 kDa recombinant proteins including the additional 6kDa His-tag/Xpress tag
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as described by the manufacture. One of the colonies labeled EB486 was subcultured and
stored.

Over expression of Recombinant Protein EB486
In order to get optimal expression of protein EB486, three conditions were considered
including culture temperature, incubation time, and variable concentrations of Larabinose. L-arabinose was used as the inducer for EB486 in the pBAD system. The
different culture temperatures included 25°C and 37°C didn’t show any differences in
protein expression. Hence, optimal growth was achieved with either temperature. The
pilot study was performed by growing the EB486 single colony in LB broth until an
optical density (O.D.600) of 0.5 and then different concentration of L-arabinose was
induced in different time of incubation of 0hr, 2hr, 4hr, 6hr, 8hr, and overnight. This
study, incubation time was found to be directly proportional to protein expression.
However, SDS gel analysis of EB486 expression of 8 hours and overnight appeared to
show more background and the presence of none specific bands. Thus, 4 to 6 hours
incubation time after induction was preferred for optimal expression of the protein. In the
case of induction by L-arabinose, varying concentrations at .0002%, 0.02%, 0.2%, and
2.%, were used to determine optimal expression. The concentration of 0.02% was
selected based on the quantity and quality of expression as shown in figure. Figure 13
illustrates the optimal expression of the 16 kDa protein from subclone EP486.
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Purification of Recombinant Protein EB486
The recombinant protein EB486 includes N-terminal polyhistidine tag and an additional
encoding sequence named Xpress as described by the manufacturer. The estimated
product of the pBAD protein product is 6 kDa. The presence of anti-His and anti-Xpress
monoclonal antibodies have facilitated in the identification and purification processes. As
shown in Figure (14), the 22 kDa (including 6 kDa from the vector) was purified which
then used in further experiments.

Construction of Subclone MS486 (M. smegmatis Subclone)
According to the multiple cloning sites (MCS) of the shuttle vector, two different
restriction enzymes, BamH I and kpn I were selected. Consequently, a new set of
oligonucleotide primers were designed and added to the 486 ORF sequence in order to be
ligated the shuttle plasmid and then ultimately transformed into M. smegmatis competent
cells. Using pMptb#28 DNA template, the 506 bp (486 ORF sequence plus cloning
enzyme sequence) was amplified by PCR, purified and then ligated into linearized shuttle
plasmid. To facilitate cloning into M. smegmatis competent cells, a transitions step was
required. Therefore, Ligation mixture first was transformed into E. coli competent cells.
Cloned plasmid was verified and then electopoareted into M. smegmatis competent cells.
As shown in Figure (16), digested plasmid from the recombinant colony#5 revealed the
presence of an estimated 506 bp insert. DNA extracted from colony #5 was further
confirmed by sequencing. After confirmation, purified extracted DNA from
E. coli colony#5 was electroporated to M. smegmatis competent cells. After 3 days many
colonies were observed. Figure (17) shows recombinant M. smegmatis colonies after 6
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days. Four of those colonies were grown in 2ml 7H9 broth in 2 days and then
transformed to 20 ml culture, then was sonicated to obtain protein extracts as described
earlier. At the protein level, protein extracts from M. smegmatis transformed with
pNEZ6.3 (as negative control), M. smegmatis transformed with pShuttle19Kand four new
M. smegmatis transformed were screened against M. smegmatis adsorbed rabbit anti-M.
paratuberculosis antibody. In Lane 1, a 19kDa antigen band was detected in the protein
extract of M. smegmatis recombinant harboring pShuttle19kDa similar to the native size
detected in the M. paratuberculosis protein extract as discussed earlier. Lanes 3,4,5 and 6
represent those new M. smegmatis recombinant colonies expressing 19kDa protein. There
was no reactivity in extracts from the host M. smegmatis (lane 2). The expressed protein
from the 486 ORF is 19 kDa compared to 16 kDa in E. coli host.

Estimation of the 486 bp ORF Encoding Product
The 486 bp ORF was translated and each amino acid molecular weight was determined.
Overall the actual calculated size of the peptide sequence encoded on the 486 bp is 15.6
kDa. This protein size is similar to that expressed in EB486 (in E. coli host) and smaller
than in M. smegmatis (SM486).
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Analysis of SM486 for Posttranslational Modification
The difference in the expressed product of the 486 bp ORF in both E. coli and M.
smegmatis (16 kDa versus 19 kDa) had suggested that M. smegmatis may support
posttranslational modification. We attempted to analyze the SM486 protein for
posttranslational Glycosylation based on some homologous identity with 19 kDa from M.
tuberculosis in the data base and the fact that E. coli does not support posttranslational
glycosylation.

Evaluation of SM486 protein for Carbohydrate Content:
By Enzymatic Deglycosylation
The simplest way to show the presence of carbohydrate on glycoproteins is by removing
the carbohydrate and then recognizing the mobility shift on SDS-PAGE gels and this was
done by using an enzymatic deglycosylation kit (E-DEGLY kit from Sigma-Aldrich).
The enzymatic method can remove the carbohydrates without any protein degradation
and this is an advantage over the chemically removing the carbohydrates from
glycoprotein. The E-DEGLY kit contains all enzymes (PNGase F, Neuraminidase, OGlycosidase, Glycosidase, N-Acetylglucosaminidase ) require to completely remove all
N-linked and O-linked carbohydrates from glycoprotein. In this experiment, Bovin fetuin
was used as positive control, which contains N-linked and O-linked oligosaccharides.
As shown in figure (20) lanes 1 and 2 contain Bovine fetuin glycoprotein before and after
deglycosylation, respectively. It was clear that there was a shift in the size of the protein
before and following the deglycosylation treatment. The observation confirms the
validity of the purchased kit to be used for evaluation of glycoproteins. When the same

41

experiment was applied on protein extracts from the recombinant M. smegmatis
expressing the 19 kDa protein, there was no shift in protein size (Figure 20, lanes 3 and
4). Protein extract from the recombinant M. smegmatis was evaluated for possible
inhibitors. In this experiment, protein extract from the recombinant M. smegamtis was
spiked with Bovine feutin glycoprotein control and then subject to enzymatic
deglycosylation. As shown in Figure20. The Feutin glycoprotein has shifted in size as
expected following the treatment illustrating absence of any inhibitors. The 19kDa
protein was not affected by the deglycosylation treatment (Figure20, lane5)
By ConA Staining:
The possible lack of glycosylation in the 19kDa protein was further evaluated by ConA
staining. ConA is a lectin that specifically binds to alpha-D-glucose and alpha-Dmannose. The protein samples analyzed earlier in Figure 20 were also evaluated
following staining an immunoblot with peroxidase-conjugate ConA. As shown in Figure
21, the Feutin glycoprotein (positive control) stained positively with ConA confirming
the presence of ConA even following the deglycosylation treatment due to presence of
remnant carbohydrates on this protein. However and most importantly, the 19kDa protein
was absent in the immunoblot stained with ConA. The observation was true for the 19
kDa before and after the deglycosylation treatment and for eluted recombinant 19kDa
protein from SDS PAGE.

Evaluation of EP486 and SM486 proteins for T-cell Proliferation Response:
In this experiment two mitogens, PHA and PWM were supplied as positive controls.
PHA is a plant mitogen and measures the overall function of lymphocyte responsiveness.
In fact, PHA stimulates directly proliferation of peripheral blood mononuclear cells by
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mechanisms different than those antigen processing and presentation to lymphocytes. In
this study, PHA was used at the final concentration of 20ug/ml, which has been identified
in our lab to present optimum lymphocyte proliferation. Another positive control, PWM,
(Pokeweed Mitogen) was used to evaluate the proliferation response of T-lymphocytes
independent to other cells such as B-lymphocytes and other antigen presenting cells.
PWM was used at final concentration of 10ug/ml.
Earlier experiments illustrated that the 486 bp encoding sequence of the 19 kDa protein
had expressed a16 kDa in E. coli and as 19 kDa in M. smegmatis. The protein expressed
in both bacterial hosts regardless in the difference in molecular weight reacted similarly
to rabbit-anti-MAP IgG antibodies. In these experiments, the protein from the two
bacterial hosts was evaluated against T lymphocytes from healthy individuals and
patients with Crohn’s disease. Protein extracts from E. coli without the gene and M.
smegmatis without the gene were also included. Additionally, purified protein from the
two hosts was also included.
The proliferative response of PBMC samples isolated from Crohn’s patient and healthy
individuals were quantitatively measured and compared. Preliminary data indicate that
there is no significant difference in the proliferative ability of this protein expressed in E.
coli compared to M. smegamatis (Table 4). T-cells from patients with Crohn’s disease
proliferative response to PHA clearly indicate a decrease in response when compared to
T- cells from normal controls (Table3, Figure 22).
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CHAPTER FOUR
DISSCUSSION
Vaccines are the most cost-effective medical intervention known to prevent disease. The
urgency for development of an appropriate multivalent vaccine vehicle against
mycobacteria is mounting. This is due to the increasing incidence of multiple drug
resistant (MDR)-M. tuberculosis strains (49, 18) and the ineffectiveness of current
therapies for the treatment of disseminated disease in AIDS patients and other
mycobacteriosis (48). Discovery of effective vaccines require identification of
appropriation antigens and their ability to modulate the immune response causing
acquired protective immunity. Proteins can be modified through glycosylation,
phosphorylation, acylation or by other mechanisms which ultimately have an impact on
their antigencity. Cloning of some mycobacterial protein E. coli may lead to expression
of proteins with smaller molecular weight than expected due to that fact that E. coli
supports limited posttranslational modification. Consequently, mycobacterial genes
should be cloned in similar hosts that may aid in the expression of the expected native
proteins. Shuttle plasmids are needed in order to accomplish such mission. Many efforts
have been expended in the construction of an appropriate shuttle vector that may be used
as a cloning vector to study mycobacterial genes or as a vehicle for the development of a
suitable vaccine. The first attempt to form an E. coli-Mycobacterium shuttle plasmid
vector was initiated by constructing a chimeric shuttle plasmid containing
mycobacteriophage DNA inserted into an E. coli cosmid (29). This shuttle plasmid
replicated in E. coli as a plasmid and in mycobacteria a phage. This was followed by the
construction of pIJ666 by Snapper et al. (1988). The application of these shuttles in
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mycobacterial genetics was limited to gene transfer with poor transfection/transformation
efficiencies and no record of expression at the protein level. Nevertheless, this was an
important step forward in gene analysis in mycobacteria. Radford et al. (1991)
constructed the shuttle plasmid pEP3 with a size of 4.5 kb, but the transformation
frequency was comparable to those obtained by Snapper. Lazraq et al. (1991)
constructed the shuttle plasmid pDC100 with a molecular size of 10.4 kb. pDC100
appeared to lack unique cloning sites and it replicated in mycobacteria at low copy
number that hampered its analysis on agarose gel. Hinshelwood et al. (1992) constructed
pMSC1 which apparently was suitable only for construction of a genomic library or
biosynthetic pathways analysis. pMSCI is a 13.1 kb and contained unique sites for
BamHI and HindIII only. In our laboratory, pNEZ6.3 was designed to overcome the
limitations of other shuttle vectors. pNEZ6.3 vector is a phagemid that can be used either
as a plasmid or a phage. In addition, the size can be reduced without loss of any
functions. pNEZ6.3 contains two multiple cloning sites downstream of the T7 and the
Sp6 promotors that enable further detailed analysis of multiple genes in one host. These
promotors facilitate in vitro transcription using T7 or Sp6 RNA polymerase and the
synthesis of an mRNA strand of the cloned gene that may be labeled and used as a
riboprobe. They are also useful for sequence analysis using one of several primers such
as T7, Universal, Sp6 or Reverse primer. The presence of F1 ori enables the rescue of
ssDNA of the cloned gene after infection of the E. coli host with an appropriate phage
such as M13. Since mycobacteria are susceptible to kanamycin, the drug resistant marker
encoded on pNEZ6.3 shuttle vector facilitates screening of recombinants in mycobacteria
. pNEZ6.3 expressed the kanamycin resistant gene in M. smegmatis whether kanamycin
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was present or absent in the media. This is contrary to report by Lazraq et al. (1991) that
pDC100 shuttle was lost when M. smegmatis was grown in media without kanamycin.
Previously in our lab, genomic library of Mycobacterium avium paratuberculosis was
constructed in E. coli. Colonies were screened for gene expression using immunoblot and
rabbit anti-M. paratuberculosis antibody. pMptb#28 recombinant clone contained and
insert of 4.8 kb and encoded for a single protein of 16kDa. Surprisingly, M.
paratuberculosis lacked a 16 kDa protein band when screened with rabbit anti-M.
paratuberculosis antibodies. When the 4.8 kb BamH I fragment was cloned in M.
smegmatis using a pNEZ6.3 shuttle plasmid, it produced a 19 kDa protein (Smeg19k)
similar to the size observed in extracts from M. parartuberculosis (Figure 3). The
observation using the shuttle technology suggested a possible posttranslational
modification in mycobacteria. In order to verify that the expression of 16/19 kDa protein
in the two different hosts is not due to switching in the starting codon, we analyzed the
4.8 kb insert for the presence of the encoding sequence ORF. Earlier in the study, the M.
paratuberculosis genome sequence was not published yet so sequencing the both ends of
the 4.8 kb insert did not reveal any breakthrough. Performing Unidirectional Deletion
using ExonucleaseIII allowed us to identify the region with possible ORF (Figure 4,5,6).
At this phase of the study, the M. paratuberculosis genome sequence was revealed. The
ends of the new subclones and using BLAST analysis with M. tuberculosis 19 kDa
encoding gene resulted in the identification of 486 bp in the 4.8 kb insert. The sequence
of 486 of ORF is including starting codon GTG and stopping codon TGA. . The 486 is
coding 161 amino acids, which has molecular weight of 15.6kDa. When the 486 bp
sequence of ORF cloned in E. coli, the expressed protein in E. coli without vector
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encoded peptide was estimated at 16kDa. However, when the same 486bp of ORF cloned
in M. smegmatis, the expressed protein was 19kDa. These results clearly showed that M.
smegmatis is able to produce 3 kDa more than the calculated size of the protein according
to the exact sequence of ORF. The difference in the sizes of the expressed protein may be
related to posttranslational modification. The lack of possible phosphorylation,
glycosylation or other posttranslational modification of the 19 kDa protein in the E. coli
host can result in the formation of a protein with smaller mass. This observation was also
reported by Garbe et al. (1993) while analyzing a 19 kDa antigen of M. tuberculosis in
M. smegmatis. In their experiment, a DNA fragment encoding the M. tuberculosis 19
kDa protein was cloned into a shuttle vector and then transformed into E. coli and M.
smegmatis. The expressed protein was 16K in E. coli and 19K in M. smegmatis. The
difference the sizes was due to the lack of glycosylation in E. coli.
The lack of complete expression of both the 19 kDa protein of M. paratuberculosis and
the 19 kDa protein of M. tuberculosis in the E. coli system is of concern to investigators
and underscores the necessity to study mycobacterial virulence antigens in a homologous
host. The role of posttranslational modification in expressed proteins especially in
immunomodulation is yet to be elucidated.
Posttranslational modification has been investigated vigorously in recent years.
Consequently, many glycoproteins (N or O-linkage) have be reported in both
archaebacteria and eubacteria (3,7,47), which defeated the dogmatic belief that
prokaryotes are unable to support posttranslational modifications such as glycosylation.
This include identification of glycoproteins Neisseria meningitidis (57), Flavobacterium
meningosepticum (45,50) Streptococcus sanguis(17), Bacillus alvei (39), Clostridium spp.
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(22,38), Bacteroides cellulosolvens (22), Thermoanaerobacter thermohydrosulfuricus (5)
and Mycobacterium

tuberculosis (12,13,7). In this study, the data clearly illustrates that M.

paratuberculosis supports posttranslational modification (Figure 3).
This study focused on glycosyslation as a possible mechanism for posttranslational
modification in the M. paratuberculosis 19 kDa protein. Following the analsysis of the
expressed 19 kDa by deglycosylation enzymatic assay and conA staining, there was clear
evidence that the modification of this protein is not due to glycosylation (Figurtes 19and
20). We strongly conclude that unlike the glycosylation of M. bovis 19kDa protein, the
19k, antigen in M. tuberculosis and the 45-k protein in M. tuberculosis (19, 20, 13, 12, 7),
the

19 kDa protein of M. paratuberxulosis is not a glycoprotein and may be subjected to

other posttranslational modification mechanism
Finally, we further investigated the role, if any, of posttranslational modification
component of the expressed 19 kDa M. paratuberculosis in the protein antigencity and
proliferative capability. Specifically, our concern focused on whether the unexpressed
portion of the protein (16 kDa in E. coli, Figure 3) may encode immunomodulatory
components that are essential in the exposure of the 19 kDa antigen during natural
infection in cattle and humans. Initially, both forms of the expressed protein (16 kDa in
E. coli and 19 kDa in M. paratuberculosis) reacted similarly to rabbit-anti-M.
paratuberculosis IgG antibodies (Figure 3). Most recently, we valuated both forms of the
19 kDa protein against T-lymphocytes derived from two healthy individuals and two
patients with Crohn’s disease. T-cell response to PHA, a non-selective mitogen, has
shown to be less in Crohn’s disease compared to healthy controls. This finding confirms
earlier observation in our lab (Romero, submitted). Preliminary data so far suggest a
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minor decrease in the proliferative response of T-cells reactivity to protein extracts
containing the 16 kDa compared to the 19 kDa forms (Table 4). This suggests that the 3
kDa component of the 19 kDa protein may not play a role in the immunogencity of the
protein.
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CHAPTER FIVE CONCLUSION
Collectively, our data show data clearly illustrate for the first time that M.
paratuberculosis supports posttranslational modification. The data confirms observation
reported in M. tuberculosis, M. bovis and M. leprae. The significance of this finding may
aid in investigating virulence in M. paratuberculosis and its pathogenesis in patients with
Crohn’s disease and animals with Johne’s disease. Our data also confirm that the
postranslational modification of this 19 kDa protein from M. paratuberculosis is not due
to Glycosylation. The presence pf series of serine in the peptide sequence of the 19 kDa
may suggest that acylation should be investigated. The role of the posttranslational
modification component seems to be limited since there was limited difference between
the two forms of the protein (16/19 kDa) against T- cell response.
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Figure 1: Isolation and Restriction Endonuclease Digestion of Extracted
Plasmid from Clone pMptb#28
Plasmid pMptb#28 and vector pcDNAII were extracted and digested by enzyme Bam HI.
Both digested and undigested plasmids were analyzed on 0.8% agarose gel.
Lane1, DNA/Hind III size standard, Lane2 and 3, Plasmid pcDNAII circular and
linearized, Lane3 and 4, Plasmid pMptb#28 undigested and digested
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Figure 2: Restriction Endonuclease Digestion of Extracted Plasmid
from Clone Smeg19k
Plasmid extraction from recombinant clone Smeg19k was performed and then treated by
restriction endonuclease digestion BamH I.
Lane 1, undigested plasmid Smeg19k, lane 2, digested plasmid Smeg19k representing
6.3kb vector and 4.8kb insertion fragment.
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Figure 3: Immunoblot Analysis of the Native 19kDa Protein (M.
paratuberculosis) and the Recombinant Proteins (E. coli, M. smegmatis)
Protein extracts of M. paratuberculosis, M. smegmatis recombinants, E. coli
recombinants were loaded on SDS-PAGE and immunoblotted against E. coli adsorbed
rabbit anti-M. paratuberculosis sera.
Lanes: 1, protein size standard, Lane2, extracts from M. paratuberculosis, Lane 3, 4,
extracts from smeg/shuttle19 and Smeg/shuttle Lane5, 6 extracts from E. colipMptb#28
and E.coli pcDNAII, Lnae7, 8 extracts from E. coli/shuttle19 and E. coli/shuttle
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Figure 4: Identification of DNA nested deletion of pMptb#28
The extracted plasmid of pMptb#28 was digested first by XhoI and then SpeI. The created
5’overhang close to insertion was susceptible to ExonucleaseIII activity. The DNA
sample was exposed to ExonucleaseIII, aliquots of deleted DNA were removed every 30
sec and then the reaction was stopped with S1 stop mixture. Deleted DNA aliquots were
analyzed by gel agarose electrophoresis.
Lane 1: Low mass DNA standards Lane 2 &20: λ Hind III size standards Lane 3 to 18
contain DNA deletion aliquots removed from 0 sec to 10 min.

55

kDa

M

1

2

3

4

5

6

20
15

Figure 5: Immunoblot analysis to identify the protein expression from
DNA nested deleted subclones
The time deleted plasmids were selected to re-circularize, then transformed to E. coli Top
10.The subclones were examined at protein level by immunoblot using rabbit anti-M.
paratuberculosis antibody to reveal the smallest plasmid that is still able to produce the
protein.
Lanes: M, protein size standard, Lane1,2,3,4,5,6 are extracts proteins from subclones
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Figure 6: Plasmid Extraction and Digestion of DNA Nested Deleted
Subclones
Plasmid extraction were carried on some of the DNA nested deleted subclones and then
linearized by restriction endonuclease kpn I. Circular and linearized plasmids from
subclones, pcDNAII and pMptb#28 analyzed on 1% agarose gel.
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Panel A: Lane M, low mass DNA ladder size standard, Lane 1-6, circular and linearized
plasmids from subclone 1,2,3,4,5,6
Panel B: Lane 1,2, low mass DNA ladder and DNA/Hind III size standard, Lane 3,
linearized pcDNAII vector, Lane 4, linearized pMptb#28 plasmid, Lane5, linearized
plasmid clone #4(the smallest plasmid, which still producing protein.
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Figure 7: PCR Analysis of 486bp ORF Region
Polymerase Chain Reaction was carried using the primers to amplify the ORF from 4.8
kb fragment in clone pMptb#28, then analyzed on 2% agarose gel.
Lane M, low mass DNA ladder standard size, Lane 2, PCR negative control, Lane 2,
second negative control when pcDNAII used as template, Lane3, PCR product 506 bp
including 486 ORF and added restriction enzyme sites.
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Figure 8: Cell Pop PCR Technique to Screen Subclones
Subclones were randomly picked as template to perform PCR using the primers. This
study was carried to identify the presence of insert (486bp ORF) without plasmid
extraction.
Lane M, low mass DNA ladder standard size, Lane 1, PCR negative control, Lane2,3,4,
PCR product of three different subclones randomly picked from the plates.
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Figure 9: Restriction Endonuclease Digestion of Extracted Plasmid
from Subclone EB486
Plasmid extraction was performed on one of the screened colony by Cell Pop PCR, and
digested by Bgl II and EcoR I to analyze on 1% agarose gel.
Lane 1, DNA/Hind III size standard, Lane 2, Digested plasmid representing 4.1kb pBAD
vector and 486bp ORF fragment.
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Figure 10: Immunoblot Analysis of Subclones (EB486) By Anti-His
Antibody
Positive subclones by Cell Pop PCR were grown in LB and induced by L-arabinose.
Then, cell lysates (induced and un-induced) were fractionated on SDS-PAGE gel and
transformed on to nitrocellulose membrane. Anti-His antibody was applied to identify the
fusion protein.
Lanes: M, protein size standard, Lane 1, Negative control,cell lysate from pBAD,.Lane
2,3 cell lysate clone #1( un-induced and induced), Lane 4,5 cell lysate
clone#2,(uninduced and induced), Lane 6,7 cell lysate clone#3( uninduced and induced),

62

kDa

M

1

2

3

4

5

6

7

8

25
20

Figure 11: Immunoblot Analysis of Subclones (EB486) By Anti-Xpress
Antibody
Positive subclones by Cell Pop PCR were grown in LB and induced by L-arabinose.
Then, cell lysates (induced and un-induced) were fractionated on SDS-PAGE gel and
transformed on to nitrocellulose membrane. Anti-Xpress antibody was used to identify
the fusion protein.
Lanes: M, protein size standard, Lane 1,2 cell lysate clone #1, un-induced and induced,
Lane 3,4 cell lysate clone#2,un-induced and induced, Lane 5,6 cell lysate clone#3, Lane
7,8 Negative control, cell lysate from pBAD, un-induced and induced.
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Figure 12: Immunoblot Analysis of Subclones (EB486) By Rabbit AntiMAP Serum
Positive subclones by Cell Pop PCR were grown in LB and induced by L-arabinose.
Then, cell lysates (induced and un-induced) were fractionated on SDS-PAGE gel and
transformed on to nitrocellulose membrane. E. coli adsorbed rabbit anti-M.
paratuberculosis sera was used to identify the fusion protein.
Lanes: M, protein size standard, Lane 1,2 cell lysate clone #1, un-induced and induced,
Lane 3,4 cell lysate clone#2,un-induced and induced, Lane 5,6 cell lysate clone#3, Lane
7,8 Negative control, cell lysate from pBAD, un-induced and induced.
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Figure 13: Optimization of Recombinant Protein EB486 Expression
Different concentration of L-arabinose (0.002%, 0.02%, 0.2%, and 2%) was induced in
different time incubation of 0hr, 2hr, 4hr, 6hr, 8hr, and overnight (picture is showing just
4 and 6 hr) to determine optimal condition for expressing the EB486 protein. Cell
extracts were fractionated on SDS-PAGE and blotted on a nitrocellulose membrane,
which screened by Anti-His antibody.
Lanes: M, An arrow on picture is showing the best condition, 0.02% concentration of Larabinose and 4 hr incubation time after induction
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Figure 14: Purification of Histidine-tagged EB486 Recombinant Protein
Recombinant EB486 protein was expressed under the optimal condition. Then cell pellet
from 200ml culture were purified using the PIERCE kit. Fractions were collected from
each of the purification steps and assayed by SDS-PAGE. Then Immunoblot was
performed using anti-His antibody.
Lane M, protein size standard, Lane 1, cell crud lysate Lane 2, flow-through, Lane 3, 4,5
three washes Lane 6,7,8,9 three Elutes
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Figure 15: PCR Analysis of 486bp ORF Region for Cloning into M.
smegmatis
Polymerase Chain Reaction was carried using the primers to amplify the ORF from 4.8kb
fragment in clone pMptb#28, then analyzed on 2% agarose gel.
Lane 1, low mass DNA ladder standard size, Lane 2, PCR product 506 bp including 486
ORF and added restriction enzyme sites (BamH I and kpn I
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Figure 16: Restriction Endonuclease Digestion of Extracted Plasmid
from E. coli Subclone (Transition)
Plasmid extraction was performed on one of the screened colony by Cell Pop PCR, and
digested by BamH I and kpn I to analyze on 1% agarose gel.
Lane M, Low mass DNA ladder and DNA/Hind III size standard, Lane 1-6, Digested
extracted plasmid from transformed colonies, Lane #5 digested plasmid representing
6.8kb shuttle vector and 486bp ORF fragment.
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Figure 17: Transformation of Shuttle vector to M. smegmatis strain
mc2155
Shuttle vector including 486 bp ORF from E. coli Subclone was electroporated to M.
smegmatis mc2 155.
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Figure 18: Immunoblot Analysis of M. smegmatis Subclones(SM486)
M. smegmatis subclones were grown in 7H10 and then sonicated. Protein extracts of M.
smegmatis recombinants were fractionated on SDS-PAGE gel and immunoblotted against
M. smegmatis adsorbed rabbit anti-M. paratuberculosis sera.
Lanes: M, protein size standard, Lane1 extracts from smeg/shuttle19(including 4.8 kb
fragment), Lane 2, Smeg/shuttle as negative control, Lane3,4,5,6 M, smegmatis
subclons (SM468)
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Figure 19: Nucleotide Sequence analysis of the 4778bp including 486bp
encoding the 19kDa protein
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Figure 20: Carbohydrate Detection: Effect of Deglycosylation on
Mobility
Silver Staining of samples before and after deglycosylation
Bovine Fetuin as positive control and cell crude lysate from recombinant clone
smeg/pShuttle 19 loaded in 12%SDS gel before and after applying deglygcosylation kit.
Lanes: 1,2 Bovine Fetuin before and after deglycosylation 3, 4 cell lysate from
recombinant clone smeg/shuttle19 before and after deglycosylation 5, spike (mix of
positive control and cell lysate smeg/shuttle19) before and after deglycosylation 6,7,
purified 19kDa recombinant protein from smeg/shuttle19k (eluted from polyacrylamide
gel) before and after deglycosylation.
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Figure 21: Carbohydrate Detection: Concanavalin-A staining
The same samples used in figure7 were analyzed by SDS-PAGE and followed staining
with peroxidase-conjugated ConA. As shown ConA was positive for Bovine fetuin
(positive control) but not in samples from smeg/shuttle19k in expected size. This
confirms the lack of glycosylation in recombinant protein produced by M. smegmatis.
Lanes: 1, protein size standard, 2,3 Bovine Fetuin before and after deglycosylation , 4,5
cell lysate from recombinant clone smeg/shuttle19 before and after deglycosylation 6,
spike (mix of positive control and cell lysate smeg/shuttle19) before and after
deglycosylation, 7,8, purified 19kDa recombinant protein from smeg/shuttle19k(eluted
from polyacrylamide gel) before and after Deglycosylation
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Figure 22: T-Cells proliferation response in Healthy controls compare
to Crohn’s diseases
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Table 3: Evaluation of PBMC Proliferative Response to PPD and
Positive Controls

Healthy control1 Normal

Normal

PPD(c)
(PPD≤10%Enviro
mental exposure)
11%

Healthy control2 Normal

Normal

10%

Healthy control3 Normal

Normal

2.5%

Crohn’s patiant1 Normal

Suppressed (40%)

16%

Crohn’s patient2 Normal

Suppressed (67%)

6.5%
(map exposure)

PWM(b)

PHA(a)

a-PHA: Phytohemagglutinin to assess the overall function of lymphocyte responsiveness
b-PWM: Pokeweed mitogen to assess B cell responsiveness dependent on T-cell
activation
c-MAP PPD: Purified protein derivative from MAP to assess previous subject’s exposure
to the bacterium
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Table 4: Evaluation of PBMC Proliferative Response to Various
Proteins

PHA
Healthy
control1

0.76

Healthy
control2

0.8

Healthy
control3

0.9

Crohn’s
patiant1
Crohn’s
patient2

0.53

Extract
Ecoli

Purified
19kDa

Purified
16kDa

0.171

Extract
Ecoli w
/insert
0.2

0.185

N/A

N/A

0.265

0.213

0.232

0.22

0.29

0.274

0.125

0.11

0.198

0.177

N/A

N/A

0.281

0.167

0.25

0.158

N/A

N/A

0.261

0.22

0.153

0.142

0.265

0.22

Extract
Smegw/
insert
0.25

Extract
Smeg

0.37

PHA: Phytohemagglutinin to assess the overall function of lymphocyte responsiveness
N/A: not enough available blood sample or protein available
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